In Russia there is a growing incidence of respiratory organs. Pharmacy sales of relevant drugs increased annually by 7-9%, the majority of patients to purchase at their own expense. A normativ budget allocations for medicines of one patient with respiratory diseases is about 10 thousand rubles a year. In such a situation to talk about using modern therapy can only theoretically.
A study on the use of medication for decenia bronchopulmonary diseases, presented to the International analytical Agency IQVIA during the XXVIII National Congress on respiratory diseases held last week in Moscow. According IQVIA in recent years in Russia uvelichivaetsya the use of drugs for the treatment of respiratory diseases, which are dominated by preparations for the treatment of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD), which indicates an increase in the number of patients suffering from respiratory diseases. So, in 2016, the Russian patients in need of 28.75 million packages of the drugs, 7.01% more than in 2015. В2017 year, that number has increased by 9.64% and times to 31.52 million packages.
In Russia COPD and asthma is related to socially significant diseases. These diseases take the third place in the overall mortality, reduce the duration and quality of life, impact on health. Patients with such diseases require a lifetime of regular use of drugs as the basic treatment for prevention of exacerbations. When establishing the degree of disability patients with asthma and COPD the necessary medications are provided through the state budget under the program of preferential medicinal maintenance. However, the majority of patients (60%) choose the monetization of benefits, and independently buy the necessary preparty, the experts found out IQVIA. And this despite the fact that the value of the monthly rate for 30-200% was higher than the amounts remitted patients with monetization.
Over 63% of the medicines used to treat COPD and asthma account for drugs emergency therapy short-range beta-agonists, according to the study. However, according to current clinical guidelines based therapy of obstructive lung diseases are a combination of drugs (broncholytic long-acting and inhaled the hormone). And already not the first year the pharmaceutical industry produces drugs of new generation, suitable for the basic treatment, and cupping.
In addition, according to participants of the National Congress, the success of the therapy of asthma and COPD depends on the patient’s compliance with rekomendovano dosage and frequency of administration of the drug. However, the majority of patients incorrectly taking medications because of the purely technical errors, for example, a person difficult to clearly synchronize respiratory efforts with the activation of desiroush device, as it is written in the instructions. In the end, in three quarters of patients the treatment does not reach the desired effect. The new generation of drugs produced in the form of a mini-inhalers clearly rasschitany amount of the drug solve this problem.
This problem is discussed in the professional community, – said directortakashi state medical University, Professor Catherine Eliseev. The existing imbalance in the therapy of COPD and asthma must be corrected, replacing the short-range beta-agonists are more effective modern combination drugs and long acting bronchodilators.
Irina Reznik